Vistagen Therapeutics Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy VTGN?
Source: PRnewswire
- Class Action Deadline: Vistagen Therapeutics (NASDAQ:VTGN) reminds stock purchasers from April 1, 2024, to December 16, 2025, that the deadline to apply as lead plaintiff is March 16, 2026, and failure to act may result in losing the opportunity to represent other investors.
- No Out-of-Pocket Fees: Investors joining the class action may receive compensation without any upfront costs through a contingency fee arrangement, which alleviates financial burdens and encourages more affected investors to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Vistagen provided overly optimistic future trial success expectations regarding its drug fasedienol while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its expertise and resource advantages in handling similar cases, prompting investors to carefully consider their choice of legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.610
Low
0.90
Averages
0.97
High
1.00
Current: 0.610
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Therapeutics Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, to apply as lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Vistagen provided overly optimistic statements regarding its drug fasedienol's development and trial success while concealing negative information related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure effective legal support and resources throughout the litigation process.
See More
Notice of Class Action Lawsuit Against Vistagen Therapeutics
- Class Action Timeline: The class action lawsuit against Vistagen Therapeutics targets purchasers of common stock from April 1, 2024, to December 16, 2025, with a deadline of March 16, 2026, for investors to apply as lead plaintiffs to represent other shareholders in the litigation.
- Lawsuit Background: The lawsuit alleges that Vistagen's management provided overly optimistic projections regarding the success of its drug fasedienol for treating social anxiety disorder while concealing significant adverse facts related to the Phase 3 trial, resulting in investor losses when the truth emerged.
- Law Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its strong expertise and track record in this field.
- Investor Action Recommendation: Investors are encouraged to visit the Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the class action and avoid inexperienced intermediary firms.
See More
Class Action Filed Against Vistagen for Investor Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit in the U.S. District Court for the Northern District of California against Vistagen on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025, aiming to protect their legal rights.
- False Statements Allegation: The complaint alleges that Vistagen made overwhelmingly positive statements regarding its PALISADE-3 trial while concealing significant adverse facts related to the study results, misleading investors in the process.
- Stock Price Plunge Impact: Following the announcement on December 17, 2025, that the trial did not meet its primary endpoint, Vistagen's stock price plummeted from $4.36 to $0.86 per share, representing a decline of over 80%, resulting in substantial losses for investors.
- Investor Action Call: The law firm encourages all affected investors to apply by March 16, 2026, to be appointed as lead plaintiffs in the lawsuit, thereby safeguarding their rights and participating in the subsequent legal proceedings.
See More
Vistagen Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the legal risks that could adversely affect the company's stock price.
- Contact Information Provided: Investors wishing to discuss their legal rights can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact numbers provided to facilitate investor inquiries.
- Market Reaction Anticipation: Given the potential impact of the legal proceedings, Vistagen's stock price may face further downward pressure, necessitating investors to closely monitor developments to safeguard their interests.
See More
Vistagen Therapeutics Investor Claim Notice
- Investor Claim Notice: Levi & Korsinsky LLP is urging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to contact them before the lead plaintiff deadline, highlighting the firm's commitment to protecting investor rights.
- Clinical Trial Progress: On April 1, 2024, Vistagen announced the enrollment of the first patient in its PALISADE-3 Phase 3 trial, with management describing this as a significant milestone in the development and commercialization of the drug candidate, indicating proactive advancements in R&D.
- Fiscal Year Performance and Enhancements: The fiscal year 2024 results revealed that COO Joshua Prince discussed notable enhancements, including in-person investigator meetings and rigorous site training, aimed at optimizing trial quality, which is crucial for the credibility of clinical outcomes.
- Trial Results Disclosure: On December 17, 2025, the company disclosed that the Phase 3 study did not show statistically significant improvement on the primary endpoint, with management characterizing the results as unexpected, potentially undermining investor confidence and raising concerns about the drug's viability.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
Vistagen Therapeutics Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, to apply as lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Vistagen provided overly optimistic statements regarding its drug fasedienol's development and trial success while concealing negative information related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure effective legal support and resources throughout the litigation process.
See More
Notice of Class Action Lawsuit Against Vistagen Therapeutics
- Class Action Timeline: The class action lawsuit against Vistagen Therapeutics targets purchasers of common stock from April 1, 2024, to December 16, 2025, with a deadline of March 16, 2026, for investors to apply as lead plaintiffs to represent other shareholders in the litigation.
- Lawsuit Background: The lawsuit alleges that Vistagen's management provided overly optimistic projections regarding the success of its drug fasedienol for treating social anxiety disorder while concealing significant adverse facts related to the Phase 3 trial, resulting in investor losses when the truth emerged.
- Law Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its strong expertise and track record in this field.
- Investor Action Recommendation: Investors are encouraged to visit the Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the class action and avoid inexperienced intermediary firms.
See More
Class Action Filed Against Vistagen for Investor Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit in the U.S. District Court for the Northern District of California against Vistagen on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025, aiming to protect their legal rights.
- False Statements Allegation: The complaint alleges that Vistagen made overwhelmingly positive statements regarding its PALISADE-3 trial while concealing significant adverse facts related to the study results, misleading investors in the process.
- Stock Price Plunge Impact: Following the announcement on December 17, 2025, that the trial did not meet its primary endpoint, Vistagen's stock price plummeted from $4.36 to $0.86 per share, representing a decline of over 80%, resulting in substantial losses for investors.
- Investor Action Call: The law firm encourages all affected investors to apply by March 16, 2026, to be appointed as lead plaintiffs in the lawsuit, thereby safeguarding their rights and participating in the subsequent legal proceedings.
See More
Vistagen Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the legal risks that could adversely affect the company's stock price.
- Contact Information Provided: Investors wishing to discuss their legal rights can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact numbers provided to facilitate investor inquiries.
- Market Reaction Anticipation: Given the potential impact of the legal proceedings, Vistagen's stock price may face further downward pressure, necessitating investors to closely monitor developments to safeguard their interests.
See More
Vistagen Therapeutics Investor Claim Notice
- Investor Claim Notice: Levi & Korsinsky LLP is urging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to contact them before the lead plaintiff deadline, highlighting the firm's commitment to protecting investor rights.
- Clinical Trial Progress: On April 1, 2024, Vistagen announced the enrollment of the first patient in its PALISADE-3 Phase 3 trial, with management describing this as a significant milestone in the development and commercialization of the drug candidate, indicating proactive advancements in R&D.
- Fiscal Year Performance and Enhancements: The fiscal year 2024 results revealed that COO Joshua Prince discussed notable enhancements, including in-person investigator meetings and rigorous site training, aimed at optimizing trial quality, which is crucial for the credibility of clinical outcomes.
- Trial Results Disclosure: On December 17, 2025, the company disclosed that the Phase 3 study did not show statistically significant improvement on the primary endpoint, with management characterizing the results as unexpected, potentially undermining investor confidence and raising concerns about the drug's viability.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
